Avastin for Prostate Cancer – Looks Like It Isn’t Going To Happen
Roche Pharmaceuticals has reported that their clinical trial of Avastin in men with advanced prostate cancer did not improve their overall life expectancy. […]
The FDA Has Approved TRELSTAR(R) 22.5 mg, The First 6-Month GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer
Watson Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Trelstar – 22.5 mg (triptorelin pamoate for injectable suspension) at a dosage which will be required only to be administered twice a year. […]
On The Horizon – Cabazitaxel Extends Life After Chemotherapy Failure
The drug is called Cabazitaxel, (it will be named Jevtana) and is made by the French company Sanofi-Aventis SA. Cabazitaxel is a chemical cousin of Taxotere (the current standard of care) and it is designed to evade the mechanism that cancer cells use to resist Taxotere, so we can assume that initially it would be [...]
No Additional Hearing at the FDA for Provenge
According to a Reuters report, a spokeswomen from the FDA said yesterday that, “There is not going to be an additional advisory committee meeting” about the current application for the approval of Provenge. The FDA has the right to convene another meeting to discuss the results of the IMPACT trial, but it now looks as [...]
Docetaxel-Based Chemotherapy with Zoledronic Acid and Prednisone in Hormone Refractory Prostate Cancer: Factors Predicting Response and Survival
We know that docetaxel chemotherapy (chemo) extends life, but which men might hope to experience an increase in survival? The Department of Urology, All India Institute of Medical Sciences, New Delhi, India performed a small study designed to evaluate the efficacy of docetaxel/prednisone and zoledronic acid in the treatment of men with hormone refractory prostate [...]
Stereotactic Radio Surgery (SRS) Successfully Treats Pain in Patients with Advanced Cancer that has Spread to Bones
According to researchers from University of Pittsburgh Cancer Institute (UPCI), Stereotactic Radio Surgery (SRS), which was developed at UPCI, can successfully control pain in patients with cancer that has spread to the spine. SRS is a procedure that precisely delivers a large dose of radiation directly to tumors. The researchers from UPCI, led by Dwight [...]
On the Horizon – A Quick Summary of the Status of Some of the Up Coming Treatments for Advanced Prostate Cancer
Provenge, a cancer vaccine, has demonstrated its ability to improve the survival of men with castrate resistant prostate cancer (CRPC). The developer, Dendreon, has submitted it latest clinical trial data to the FDA for approval. We hope to have an approval by mid-year 2010. Growth factors were thought to be potential targets for treating prostate [...]
Dendreon Finally Completes Its FDA Submission for the Approval of Provenge
Finally, on Monday, Dendreon announced that it completed its Food and Drug Administration (FDA) application for the approval of Provenge (sipuleucel-T). Provenge is designed as a vaccine that stimulates the body's own immune system to fight prostate cancer. It is a different type of vaccine from what most of us knows as it is given [...]
On the Horizon – Phase III Trial of MDV3100 in Advanced Prostate Cancer Begins
Medivation, Inc. (MDVN) has formally begun its phase III trial of the investigational drug MDV3100 with men who have advanced prostate cancer. The clinical trial known as AFFIRM will evaluate the novel androgen receptor antagonist, MDV3100, in men with castration-resistant prostate cancer who were previously treated with docetaxel-based chemotherapy. AFFIRM is a randomized, placebo-controlled, double-blind, [...]
Does ADT3 Work for Men with A Biochemical Prostate Cancer Recurrence?
One of the most heated debates in prostate cancer care is around the use of 5-reductase inhibitors (5ARI) like Dutasteride as a third component of a hormone blockade (ADT3). 5-ARIs block the conversion of testosterone to dihydrotestosterone (DHT). DHT is thought to be an extremely powerful “fuel” for the growth of prostate cancer. However, there [...]